Ikbal Inanli

Dr. Ikbal Inanli

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2019 in Nordic Journal of Psychiatry
Verified
Journal Article
Closed access
IIIkbal Inanli
Ikbal Inanli
MAMemduha Aydin
Memduha Aydin
AÇAli Metehan Çaliskan
Ali Metehan Çaliskan
IEIbrahim Eren
Ibrahim Eren
Background: Currently, increasing evidence supports the hypothesis that alterations in the immune-inflammatory system are critical for the pathophysiology of bipolar disorder (BD). Neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), monocyte/lymphocyte ratio (MLR), and mean platelet volume (MPV) have recently been investigated as inexpensive and simple inflammatory markers. Aims: The aim of this study is to compare NLR, PLR, MLR, and MPV in depressive, manic, and euthymic patients with BD and healthy controls, and to evaluate whether values of NLR, PLR, MLR, and MPV are possible state or trait biomarkers in BD. Methods: This retrospective study was conducted with 341 patients with BD (100 patients in a depressive state, 141 patients in a manic state, and 100 patients in a euthymic state) and 114 healthy controls. Results: We found that patients with BD in manic states had higher levels of MPV, NLR, and MLR, and patients with BD in depressive states had higher levels of MPV than the controls. Moreover, MPV predicted all states of BD, while NLR and MLR predicted the manic state of BD. Conclusions: NLR, MLR, and MPV obtained from simple and inexpensive blood tests were significantly higher in patients with BD than in healthy controls, which each imply low-grade inflammation. MPV may serve as a possible trait biomarker of BD, while NLR and MLR may both serve as possible state biomarkers of the manic state.

7 March 2025 in Clinical Psychopharmacology and Neuroscience
Verified
Journal Article
Open access
PDF file
MAMedine Gıynaş Ayhan
Medine Gıynaş Ayhan
HÖHazel Demiröz Öztürk
Hazel Demiröz Öztürk
IIİkBal İnAnlı
İkBal İnAnlı
Medine Gıynaş Ayhan, Hazel Demiröz Öztürk, İkbal İnanlı. Clin Psychopharmacol Neurosci 2025;23:391-9. https://doi.org/10.9758/cpn.24.1260

18 March 2021 in Anadolu Psikiyatri Dergisi-Anatolian Journal Of Psychiatry
Verified
Journal Article
Open access
AÇAli Çalışkan
Ali Çalışkan
IIİkBal İnAnlı
İkBal İnAnlı
SÇSıla Çalışkan
Sıla Çalışkan
IEİbRahim Eren
İbRahim Eren
Pregabalin is a γ-amino butyric acid analogue drug that is used in fibromyalgia, neuropathic pain associated with diabetic peripheral neuropathy, spinal cord injury, and postherpetic neuralgia. Symptoms reported in association with pregabalin withdrawal include insomnia, gastrointestinal distress, tachycardia, and headache. This case report describes a 68-year-old patient who developed delirium after experiencing pregabalin withdrawal. Clinicians should be aware of the possibility of pregabalin withdrawal delirium.

1 December 2014 in Klinik Psikofarmakoloji Bülteni / Bulletin of Clinical Psychopharmacology
Verified
Journal Article
Open access
PDF file
IIIkbal Inanli
Ikbal Inanli
TETahsin Etli
Tahsin Etli
HOHalil Ibrahim Ozturk
Halil Ibrahim Ozturk
AEAssoc. Prof. Ibrahim Eren
Assoc. Prof. Ibrahim Eren
Valproic acid is a widely used drug in various medical situations and settings. The occurrence of pleural effusion due to the use of valproic acid is very rarely encountered. Here, we present a case diagnosed with bipolar disorder, who had used valproic acid for a year. Pericardial and pleural effusion was determined in the case during the treatment. To the best of our knowledge, the presented case is the first to report the concurrent development of exudative pericardial and pleural effusion arising from the use of valproic acid.

1 February 2024 in Current Psychiatry Research and Reviews
Verified
Journal Article
Closed access
PDF file
IIİkBal İnAnlı
İkBal İnAnlı
Introduction: Lithium is an effective mood stabilizer. In patients with bipolar disorder using long-term lithium, discontinuation of lithium can lead to severe clinical outcomes such as lithium-induced discontinuation refractoriness. We present two clinical cases of lithium- induced discontinuation refractoriness. Case Presentation: We present two female patients with a good long-term response to lithium. Both patients did not have a mood episode for many years and had residual symptoms. The first patient discontinued lithium voluntarily, while the second patient discontinued lithium treatment due to impaired thyroid function. Lithium was added to the treatment of both patients, but lithium-induced discontinuation refractoriness developed. Conclusion: It should be kept in mind that it may develop refractoriness to lithium when deciding to discontinue lithium treatment, especially in patients with a good long-term response to lithium.

7 March 2025 in Journal of Loss and Trauma
Verified
Journal Article
Closed access
İTİbrahim Taş
İbrahim Taş
IIİkBal İnAnlı
İkBal İnAnlı